LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer Novel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney ...

Bladder cancer is one of the most common malignant tumors in urinary system, and the treatment faces huge challenges. Radical cystectomy (RC) is the primary treatment for invasive cases, yet the ...

Bladder cancer continues to pose a significant clinical challenge, with accurate imaging and treatment evaluation remaining pivotal in guiding patient management. Recent advances in imaging techniques ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Ten years ago, a discussion in Milan set a demanding project in motion. In a meeting between a biologist and a urologist, one ...

After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...

According to Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of the same physiological elements and processes as the heart. Luckily for the fields of ...

PITTSBURGH, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed ...